CERHUM
CERHUM is a Belgian medical device company founded in 2015 that manufactures patient-specific 3D-printed bioceramic (hydroxyapatite) bone grafts under its MyBone brand, selling directly to maxillofacial, orthopedic, dental, cranial, and spine surgeons across Europe under EU MDR 2017/745 authorization.
- Company typePrivate
- Founded2015
- HeadquartersLiège, Belgium
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CERHUM does
CERHUM SA is a privately held Belgian medical device company founded in 2015 and headquartered in Liège. The company manufactures patient-specific, 3D-printed bioceramic bone grafts and implants under its MyBone brand. Its core technology combines additive manufacturing with synthetic hydroxyapatite and a patented interconnected (gyroid) porous structure that preclinical studies indicate promotes vascularization and achieves 5x faster osteointegration than conventional porosity designs.
CERHUM's primary commercial product is MyBone Custom, which is authorized under EU MDR 2017/745 (registered with Belgian FAMHP, BE/CA01/1-72228) and manufactured under ISO 13485:2016 quality systems. The company serves maxillofacial, orthopedic, dental, cranial, and spine surgeons, with documented cases at CHR Liège, UZ Leuven, and Toulouse University Hospital (including a world-premiere nasal reconstruction). The patient-specific workflow involves collaborative virtual surgical planning and co-design with surgeons, with drillable implants enabling intraoperative adaptation.
CERHUM operates a high-touch B2B enterprise sales model, selling one-time patient-specific implants directly to hospitals and surgical teams. Its distribution footprint is currently regional (Belgium and France). The company appears to be founder-owned with no disclosed institutional funding or external investors identified. Its primary strategic priorities are broadening indications (maxillofacial into dental, oncology, orthopedics, cranial, spine) and scaling European distribution under its first-mover MDR authorization for 3D-printed bioceramic bone grafts.
CERHUM firmographics
Firmographics- Name
- CERHUM
- Legal name
- CERHUM SA
- Website
- https://cerhum.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CERHUM is a Belgian medical device company founded in 2015 that manufactures patient-specific 3D-printed bioceramic (hydroxyapatite) bone grafts under its MyBone brand, selling directly to maxillofacial, orthopedic, dental, cranial, and spine surgeons across Europe under EU MDR 2017/745 authorization.
- Ownership category
- akta.pro rank
CERHUM industry classification
Industry- Product category
- Medical Device - Patient-Specific 3D-Printed Bioceramic Bone Grafts
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Dental Equipment and Supplies Manufacturing (339114)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ)
- akta.pro secondary industries
- Medical & Dental 3D Printing Services (patient-specific devices, dental labs) (IMAAADAG), 3D Printing/Additive Manufacturing for Dental Prosthetics (HLABAJAF), Dental Implant Surgery & Bone Grafting (HLABAEAB), Dental Implants & Prosthodontic Components (Implants/Abutments/Prosthetics) (HLAHAEAE), Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)
Keywords
Where CERHUM is headquartered
LocationHeadquarters
- HQ city
- Liège
- HQ country
- Belgium
- HQ region
- Europe
Offices1 record
Markets served
CERHUM business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Personnel, Others, Marketing or Sales
Revenue model
- Patient-Specific Bone Graft Sales: Manufacturing and commercial sale of patient-specific 3D-printed bioceramic bone grafts (MyBone) to maxillofacial and orthopedic surgeons for bone reconstruction procedures
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
CERHUM product offering
Product offeringCore offering
CERHUM designs and manufactures patient-specific 3D-printed bioceramic bone grafts and implants (MyBone Custom) made from synthetic hydroxyapatite for maxillofacial, orthopedic, dental, cranial, and spine bone reconstruction. The company works directly with surgeons through virtual surgical planning and implant co-design to deliver custom implants featuring a patented interconnected porous structure for fast vascularization and osteointegration. The offering is ISO 13485:2016 certified and EU MDR 2017/745 authorized, sold B2B to healthcare providers across Europe.
Product overview
CERHUM offers patient-specific bioceramic bone grafts and implants through its MyBone Custom product line. The company manufactures 3D-printed hydroxyapatite bone grafts for maxillofacial surgery, including three main application areas: facial contouring (for symmetrization, gender affirmation, and aesthetic procedures), reconstructions (for trauma and tumor cases), and orthognathic surgery (for jaw realignment procedures with consolidation risks). The MyBone Custom product is enhanced by a patented interconnected porous structure optimized for fast vascularization, enabling rapid bone regeneration and osteointegration.
Differentiator
Problem solved
Functional benefit
Products and services
- MyBone Custom Patient-specific 3D-printed bioceramic bone grafts and implants made of 100% synthetic hydroxyapatite with a patented interconnected porous structure, designed for maxillofacial and orthopedic bone repair and reconstruction. Sold directly to surgeons and hospitals with collaborative virtual surgical planning and implant co-design.
Quantifiable outcome
- 5x faster osteointegration compared to conventional porosity designs
- +2 more outcomes
Companies that use CERHUM
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles2 records
CERHUM technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
CERHUM partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- 3D-SidecoreCERHUM manufactures patient-specific bone grafts on the 3D-Side Customize platform, an online platform that is part of the surgeon's journey and enables the manufacture of very specific grafts that fit patient needs.
- 3D HEALS LLCminorCollaborated on a webinar about 3D printing and bioprinting bone, with CERHUM presenting their expertise in printing bone to repair patients.
- SGScoreSGS provides ISO 13485 certification services for CERHUM's quality management system, confirming the company's compliance with medical device quality standards.
- FAMHP (Belgian Competent Authority)coreBelgian Federal Agency for Medicines and Health Products registered CERHUM's MyBone device under MDR 2017/745 (registration number BE/CA01/1-72228).
Scale indicators4 records
Recent moves5 records
Expansion highlights6 records
CERHUM competitors and assessment
Company assessmentDirect peers
- Conformis: Conformis pioneered patient-specific orthopedic implants (knee), serving as a comparable model for custom-manufacturing go-to-market in surgical implants that CERHUM is pursuing in bone grafts.
- Materialise: Materialise's medical division prints patient-specific implants, surgical guides, and CMF models, overlapping with CERHUM's patient-specific 3D-printed implant and virtual surgical planning workflow.
- Xilloc: Xilloc manufactures patient-specific 3D-printed implants (including CMF/cranial and orthopedic) and operates in the same patient-specific PSI space as CERHUM's MyBone Custom line.
- Osteopore International: Osteopore commercializes 3D-printed bioresorbable implants for CMF, orthopedic, and dental applications; directly comparable to CERHUM's 3D-printed bioceramic bone graft offering.
Broad incumbents
- DePuy Synthes (Johnson & Johnson MedTech): DePuy Synthes offers a broad CMF and trauma implant portfolio including 3D-printed CMF plates; it is the dominant incumbent CERHUM must displace in European operating rooms.
- Stryker: Stryker is a broad orthopedic/CMF incumbent with patient-specific 3D-printed CMF solutions (e.g., Tritanium/PSI portfolio); competes for the same surgeon customers as CERHUM in trauma and reconstruction.
- Medtronic: Medtronic has spinal and CMF bone graft substitute offerings (e.g., INFUSE) that compete with CERHUM in spine and orthopedic bone reconstruction.
- 3D Systems (Healthcare): 3D Systems Healthcare provides patient-specific 3D-printed surgical solutions and has historical CMF/PSI capabilities, making it a broader incumbent in patient-specific implant printing vs. CERHUM's focused bioceramic offering.
- Zimmer Biomet: Zimmer Biomet is a broad orthopedic and dental implant incumbent with bone graft substitute products; relevant comparable for the dental/orthopedic indications CERHUM is targeting.
Emerging players
- Particle3D: Particle3D is an emerging Danish player developing 3D-printed patient-specific bone implants using resorbable biomaterials; competes in the same custom-bone-graft category at an early commercial stage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
CERHUM social profiles
Digital presenceCERHUM compliance and trust
Trust signalCompliance2 records
CERHUM financial estimates
Financial estimateRevenue estimate
Valuation estimate
CERHUM leadership team
Management profileNumber of profiles
Profiles3 records
CERHUM funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CERHUM M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CERHUM
What does CERHUM do?
CERHUM designs and manufactures patient-specific 3D-printed bioceramic bone grafts and implants (MyBone Custom) made from synthetic hydroxyapatite for maxillofacial, orthopedic, dental, cranial, and spine bone reconstruction. The company works directly with surgeons through virtual surgical planning and implant co-design to deliver custom implants featuring a patented interconnected porous structure for fast vascularization and osteointegration. The offering is ISO 13485:2016 certified and EU MDR 2017/745 authorized, sold B2B to healthcare providers across Europe.
Is CERHUM a public or private company?
CERHUM is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was CERHUM founded?
CERHUM was founded in 2015. It employs 11 to 50 people.
Where is CERHUM based?
CERHUM is headquartered in Liège, Belgium, in the Europe region.
How does CERHUM make money?
One revenue line is on record: patient-Specific Bone Graft Sales.
Who are CERHUM's main competitors?
Direct peers on record are Conformis, Materialise, Xilloc and Osteopore International. Broad incumbents are DePuy Synthes (Johnson & Johnson MedTech), Stryker, Medtronic, 3D Systems (Healthcare) and Zimmer Biomet. Particle3D is listed as an emerging player.
Does CERHUM have an API?
No public API is recorded for CERHUM.
What industry is CERHUM in?
CERHUM's product category is Medical Device - Patient-Specific 3D-Printed Bioceramic Bone Grafts. Its primary akta.pro industry code is HLAHAEAJ, 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial), with a secondary code of IMAAADAG, Medical & Dental 3D Printing Services (patient-specific devices, dental labs). Its NAICS code is 339113 and its SIC code is 3842.